For years, the flares and decoys that Chemring makes to protect military aircraft from heat-seeking and radar-guided missiles were the steady, unglamorous end of the defence market. That has changed quickly. In the six months to 30 April 2026, order intake in the group's Countermeasures Business jumped by 486% to £123m, and in June the US Department of War handed its Alloy Surfaces Subsidiary a five-year contract framework worth up to $300m for airborne decoys — only months after Chemring had put that very business under strategic review.
The drivers are rising defence budgets across NATO, governments rebuilding stocks of expendable munitions and a push for secure, local Supply chains. Chemring, with countermeasure plants in the US, UK and Australia, is well placed to benefit.
Yet at 536.5p on 22 September 2026, the shares sit well below August's 52-week high of 650p, as investors weigh strong Demand against a softer UK business, rising Debt and a change of chief executive.
How the business makes money
Chemring (LSE:CHG) reports two segments. Countermeasures & Energetics makes airborne and naval decoys, plus the energetic materials — propellants, explosives and pyrotechnic devices — used in missiles, rocket motors and aircrew systems. Contracts are often long-term and sole-source.
Sensors & Information combines US-made chemical and biological threat detectors with Roke, the UK cyber and electronic warfare specialist, whose reliance on British government work makes it sensitive to Whitehall budgeting. In June 2025 Chemring added Landguard Systems, a software-defined radio business, to Roke for up to £20m.
Recent performance
In the year to 31 October 2025, Revenue rose 2% to £497.5m, underlying operating profit increased 6% to £73.5m (a 14.8% margin) and underlying Diluted Earnings per Share edged up 3% to 19.4p. The total Dividend was raised 3% to 8.0p. Most strikingly, the order book climbed 32% to a record £1,345m, and cash conversion improved to 114%.
The first half of the 2026 financial year showed a business pulling in two directions. Group revenue grew 7% to £237.3m, but underlying operating profit slipped 8% to £24.5m and underlying diluted EPS fell to 6.1p from 6.6p. Underneath, Countermeasures & Energetics had a strong period: revenue rose about 9% to £142.1m and underlying operating profit climbed roughly 32% to £26.1m, lifting the Margin to 18.4% from 15.2%.
Sensors & Information was the drag. Revenue edged up to £95.2m, but operating profit dropped to £9.6m from £16.1m. Management blamed lower utilisation at Roke, business mix and early sales of its new CORTEXA counter-drone system, with UK contracts held up by the delayed Defence Investment Plan. Chemring kept Roke's specialists in place, betting on a recovery.
The Interim Dividend was lifted 4% to 2.8p, and the group order book reached another record of £1,399.4m. The Board kept its full-year expectations unchanged, noting that 91% of expected 2026 revenue was already delivered or contracted at the end of April.
Strategy and catalysts
The central plank of strategy is capacity. Chemring is expanding energetics production at three sites: Chicago (complete and ramping), Ardeer in Scotland (commissioning) and Norway, where the first phase of work at Chemring Nobel is finished and a second is under way. Capital spending hit £44m in the first half alone. Management expects these projects, once complete, to add around £100m of annual revenue and about £30m of annual operating profit from 2028, and it retains an ambition to double group revenue to roughly £1bn by 2030.
Countermeasures has its own turnaround story. In November 2025, citing weak US demand for special material decoys, Chemring began exploring Options for Alloy Surfaces, including a sale, and classed it as a discontinued operation. The June 2026 awards — the IDIQ framework, with $35m a year guaranteed for the first three years, plus a $45m agreement to sustain the industrial base — will restart Manufacturing in Philadelphia, with deliveries due from early in the 2028 financial year. Separately, the group booked a £6.7m Impairment on retiring legacy countermeasure operations in Tennessee.
Other catalysts include a sole-source US biological detection contract (JBTDS) worth up to $48.8m, announced in July 2026, and Roke's target of more than £250m of revenue by 2028. Leadership is changing too: Michael Ord retires after eight years, and Tom Newman, from Babcock, joins as CEO designate on 5 October 2026, taking over on 1 January 2027.
Valuation talking points
At 536.5p, Chemring's Market Value is about £1.45bn. On 2025's underlying diluted EPS of 19.4p, the shares trade at roughly 28 times trailing earnings, and the Dividend Yield is below 1.5%. That is a premium rating for a company whose earnings fell in the first half, so the market is clearly paying for the 2028 capacity uplift and the 2030 revenue ambition rather than near-term profits.
Leverage is rising. Net debt stood at £144.5m at 30 April 2026, or 1.47 times rolling EBITDA, up from 0.98 times a year earlier, reflecting capital spending and buybacks. That is still moderate, but limits flexibility if projects overrun.
The bull case
- Countermeasures orders surged in the first half, and supply of qualified decoys and flares remains tight across NATO.
- A record order book of almost £1.4bn provides unusually strong revenue visibility.
- Energetics capacity expansion is targeted to add around £30m of annual operating profit from 2028.
- US Defense Production Act funding has revived Alloy Surfaces, turning a problem asset into a growth option.
- Roke's counter-drone and electronic warfare products address fast-growing areas of defence spending.
The bear case
- Sensors & Information profits fell sharply, and recovery depends on the timing of UK government spending decisions.
- Net debt has risen to nearly 1.5 times EBITDA while heavy capital spending continues.
- A trailing earnings multiple close to 28 leaves little room for delays or disappointments.
- Alloy Surfaces deliveries do not start until 2028, and US defence demand has swung sharply before.
- A new chief executive arrives in the middle of a large investment programme, adding execution risk.
The bottom line
Chemring's countermeasures really are in hot demand, and the first-half numbers prove it: sharply higher orders, rising margins in its largest segment and a revived US decoy plant. The group's energetics expansion looks well timed for a world rearming at pace.
The counterweight is that growth is expensive to build and the market has already priced in much of it. Investors will want evidence that Roke's slowdown is temporary, that capacity projects land on time and that the CEO handover goes smoothly.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...